5-(N,N-dimethyl)-Amiloride (hydrochloride): Precision NHE1 Inhibition for pH and Sodium Transport Research

Executive Summary: 5-(N,N-dimethyl)-Amiloride (hydrochloride) (DMA; SKU C3505) is a crystalline, water-soluble small molecule that potently inhibits Na+/H+ exchanger isoforms NHE1, NHE2, and NHE3, with Ki values of 0.02, 0.25, and 14 µM, respectively [APExBIO]. It is highly selective for these isoforms, displaying minimal effect on NHE4, NHE5, and NHE7, thus allowing precise modulation of intracellular pH and sodium flux [Chen et al., 2021]. DMA is widely leveraged in models of ischemia-reperfusion injury and cardiovascular research. The compound is also documented to inhibit ouabain-sensitive ATPase activities and alanine uptake in hepatic models, indicating broader effects on ion metabolism. Proper storage and use protocols are essential for reproducible results, as the compound is stable at -20°C but not intended for long-term solution storage.

Biological Rationale

The Na+/H+ exchanger (NHE), particularly the NHE1 isoform, is pivotal for maintaining intracellular pH and cell volume by extruding protons in exchange for sodium ions in mammalian cells [Chen et al., 2021]. Dysregulation of NHE1 activity is implicated in pathological conditions including cardiac ischemia, sepsis-induced endothelial dysfunction, and multi-organ failure. Elevated NHE1 activity can exacerbate sodium overload, leading to cytosolic calcium accumulation and contractile dysfunction in cardiac tissue. In endothelial injury models, NHE1 signaling intersects with cytoskeletal regulation and inflammatory cascades, such as those mediated by NF-κB and moesin phosphorylation, highlighting the broad relevance of NHE modulation [Chen et al., 2021].

Mechanism of Action of 5-(N,N-dimethyl)-Amiloride (hydrochloride)

5-(N,N-dimethyl)-Amiloride (hydrochloride) acts as a reversible, competitive inhibitor of the Na+/H+ exchanger. It binds to the extracellular domain of NHE isoforms, effectively blocking proton extrusion and sodium influx at nanomolar concentrations for NHE1 (Ki = 0.02 µM) [APExBIO]. This inhibition leads to intracellular acidification and reduced sodium accumulation, directly impacting ion homeostasis and downstream signaling. DMA displays high selectivity, with a pronounced preference for NHE1 over NHE2 (Ki = 0.25 µM) and markedly lower potency for NHE3 (Ki = 14 µM), and minimal effect on NHE4/5/7. Additionally, DMA interferes with ouabain-sensitive ATPase activity in rat liver plasma membranes and reduces alanine uptake in hepatocytes, suggesting secondary effects on broader ion and metabolite transport systems [Internal: DDP-4].

Evidence & Benchmarks

• DMA inhibits NHE1 with a Ki of 0.02 µM under physiological buffer conditions (APExBIO, product page).
• DMA blocks NHE2 (Ki = 0.25 µM) and NHE3 (Ki = 14 µM), but has minimal effect on NHE4, NHE5, and NHE7 (APExBIO, product page).
• DMA normalizes sodium overload and prevents contractile dysfunction in cardiac ischemia-reperfusion models (see Figure 3, https://doi.org/10.1155/2021/6695679).
• DMA inhibits ouabain-sensitive ATPase and Na+/K+ ATPase activities in rat liver plasma membrane fractions (APExBIO, product page).
• DMA reduces alanine uptake in isolated hepatocytes, confirming effects on amino acid and ion co-transport (APExBIO, product page).
• DMA is soluble up to 30 mg/ml in DMSO or DMF and stable when stored at -20°C for 12 months (APExBIO, product page).
• DMA is used to model sodium-driven endothelial injury, supporting studies of moesin phosphorylation and NF-κB pathway activation in sepsis (Chen et al., 2021).
• Compared to non-selective inhibitors, DMA enables more robust, reproducible control of intracellular pH and sodium levels in cardiovascular and endothelial assays (internal DDP-4 article).

Applications, Limits & Misconceptions

DMA's primary applications include:

• Modeling and modulating Na+/H+ exchanger signaling in cardiovascular disease, especially ischemia-reperfusion injury and contractile dysfunction.
• Probing intracellular pH regulation and sodium ion flux in mammalian cell systems.
• Assessing metabolic and transporter activity in hepatic and endothelial cell models.
• Elucidating pathways of endothelial injury, such as those involving moesin phosphorylation and NF-κB activation in sepsis (Chen et al., 2021).

Interlinking context: While '5-(N,N-dimethyl)-Amiloride Hydrochloride: Transforming NH...' highlights DMA's high affinity for NHE1, this article extends the discussion by detailing quantitative inhibition benchmarks and implications for ATPase activity. Similarly, '5-(N,N-dimethyl)-Amiloride Hydrochloride: A Powerful NHE1...' focuses on the role in Na+/H+ exchanger signaling, which this review clarifies with updated storage, use, and specificity data. For workflow and assay optimization, 'Optimizing Na+/...' is complemented by this article's evidence on hepatic and ATPase benchmarks.

Common Pitfalls or Misconceptions

• DMA is not effective for NHE4, NHE5, or NHE7 inhibition; selectivity is limited to NHE1, NHE2, and NHE3 (APExBIO).
• DMA solutions are unstable for long-term storage; always prepare fresh working solutions and store powder at -20°C.
• DMA is not intended for diagnostic or therapeutic use; it is for research use only (APExBIO).
• DMA may have off-target effects on ATPase activity and amino acid transport; controls should be used in metabolic studies.
• DMA should not be used in assays requiring non-DMSO/DMF solvents above 30 mg/ml solubility.

Workflow Integration & Parameters

DMA (SKU C3505) from APExBIO is supplied as a crystalline solid and should be stored at -20°C, protected from light and moisture. Solutions can be prepared up to 30 mg/ml in DMSO or DMF; aqueous solubility is significantly lower. For cell-based assays, typical working concentrations range from 0.05 to 10 µM, depending on isoform specificity and application. Rapid addition to culture or perfusion systems is recommended, as DMA may degrade upon prolonged exposure to aqueous buffers. Controls should include vehicle (DMSO) and, where relevant, non-selective NHE inhibitors. For optimal reproducibility, use within one month of solution preparation. DMA is not suitable for in vivo diagnostic or therapeutic administration. Refer to the C3505 product page for updated protocols and material safety information.

Conclusion & Outlook

5-(N,N-dimethyl)-Amiloride (hydrochloride) offers precise, high-affinity inhibition of NHE1, enabling robust modeling of sodium and pH regulation in mammalian cells. Its validated use in cardiac and endothelial assays makes it indispensable for disease mechanism research, particularly in ischemia-reperfusion and sepsis models. Researchers should rigorously control for off-target effects and adhere to recommended storage and use parameters to maximize reproducibility. APExBIO provides reliable access to this compound for advanced workflows. Future studies may expand its utility to novel metabolic and signal-transduction models, but its use remains restricted to preclinical research.